Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells
- 1 September 2011
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 122 (3) , 656-662
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancerCancer, 2010
- Ten‐year follow‐up of a phase 2 study of dose‐intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor‐prognosis, advanced‐stage epithelial ovarian cancerCancer, 2010
- Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer CellsClinical Cancer Research, 2010
- Overexpression of protease inhibitor‐dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivoCancer Science, 2009
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker StudiesPLOS Medicine, 2008
- Herpes Simplex Virus Downregulates Secretory Leukocyte Protease Inhibitor: a Novel Immune Evasion MechanismJournal of Virology, 2008
- Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer InvasionMolecular Cancer Research, 2008
- The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cellsCarcinogenesis, 2007
- INNATE HOST DEFENSE FUNCTIONS OF SECRETORY LEUCOPROTEASE INHIBITORExperimental Lung Research, 2007
- Aberrant mucosal wound repair in the absence of secretory leukocyte protease inhibitorThrombosis and Haemostasis, 2004